Exciting Half-Yearly Results Announcement by IBA

Important Announcement Regarding IBA's Half-Year Results
HY25 results webcast scheduled for
Thursday, 28 August 2025 at 3pm CEST
Louvain-la-Neuve, Belgium - IBA (Ion Beam Applications S.A.), a leader in particle accelerator technology, will share its consolidated results for half-year 2025 on Thursday, 28 August 2025 at 7am CEST.
Details About the Conference Call
IBA's management team is set to conduct a conference call and webcast in English to discuss the half-year results, followed by an interactive Q&A session.
Schedule and Access Information
This conference call is planned for Thursday, 28 August 2025, at 3pm CEST / 2pm BST / 9am EDT / 6am PDT in the form of a Teams webinar. Ensure your participation by registering through this registration link. It is important to complete the registration at least 15 minutes prior to the event.
Where to Find the Presentation
Attendees can access the presentation on the investor relations section of IBA's website and additional related materials will be available shortly before the call.
Best Practices for Connection
To prevent any delays, it is highly recommended that users register at least 10 minutes in advance of the scheduled webcast.
Additional Information for Participants
If you don't have the Teams application installed, please review the instructions provided here for optimal access to the conference.
About IBA
IBA stands at the forefront of particle accelerator technology, specializing in providing equipment and services for proton therapy, which is seen as the most advanced form of radiation therapy. The company also significantly contributes to industrial sterilization, radiopharmaceuticals, and dosimetry. With a team of around 2,100 dedicated professionals worldwide, IBA is recognized as a certified B Corporation, reflecting its commitment to high standards of social and environmental performance.
Market Position
Listed on the EURONEXT exchange, IBA is continuing to expand its influence in the realms of healthcare and technology, providing cutting-edge solutions for oncology treatment and beyond. The company's listings include IBA: Reuters IBAB.BR and Bloomberg IBAB.BB.
CONTACTS
Thomas Pevenage
Investor relations
+32 10 475 890
investorrelations@iba-group.com
Olivier Lechien
Corporate Communication Director
+32 10 475 890
communication@iba-group.com
Frequently Asked Questions
1. When will IBA announce its half-year results?
IBA is set to announce its half-year results on Thursday, 28 August 2025.
2. How can I join the conference call?
You can join the conference call by registering through a specific link shared in the announcement.
3. Where can I find the presentation for the results?
The presentation will be available on IBA's investor relations webpage and linked prior to the call.
4. What is the significance of IBA's role in proton therapy?
IBA leads in providing advanced solutions for proton therapy, a critical treatment method in oncology.
5. How many employees does IBA have?
IBA employs around 2,100 individuals globally, reinforcing its presence in the accelerator technology sector.
About The Author
Contact Logan Wright privately here. Or send an email with ATTN: Logan Wright as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.